Antiviral treatment perspective against Borna disease virus 1 infection in major depression: a double-blind placebo-controlled randomized clinical trial

Table 2 Primary clinical outcomes

Patients N = 33	Differences A vs. P^a	Patients with Amantadine(A) N = 16	Patients with Placebo (P) N = 17
Response		13	6
Non-response		3	11
Response rate (%)		13/16 = 0.8125 (81.25%)	6/17 = 0.3529 (35.29%)
Statistical significance (defined as p < 0.05)	p = 0.003
Absolute response difference	81.25–35.29 = 45.96%
Relative response (RR)	81.25/35.29 = 2.302
Odds		13/3 = 4.33	6/11 = 0.55
Odds ratio (OR)	4.33/0.55 = 7.872
Effect size of difference (expressed as Cohen’s d)	d = 1.0461
Effect size of difference (expressed as Hedges’s g)	g = 1.0175
Effect size of association (correlation coefficient r)	r = 0.463

^aPrimary outcome defined as changes between pre-treatment scores and scores at week 7 of the HAMD (DHAMD). Clinical endpoint defined as reduction of HAMD ≥25%. Time endpoint: 7 weeks

ISSN: 2050-6511